In HER2-positive gastric cancers, the phase II/III trial MOUNTAINEER-02 is currently recruiting patients eligible for second-line systemic therapies who have previously been treated with a HER2-directed antibody (NCT04499924) [89]. This evidence concerns the gene ERBB2 and gastric cancer.